The Extended LAST STRONG study is expected to provide comprehensive long-term natural history data, which can be used to further select relevant clinical and functional outcome measures to achieve trial readiness in SELENON-RM and LAMA2-MD patients. This evidence concerns the gene LAMA2 and Menkes disease.